Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIWA: Rivaroxaban vs Warfarin in Mechanical Heart Valves
NCT03566303Phase 3
Key facts
- Status
- Terminated
- Start
- Jul 2018
- Primary completion
- Apr 2020
- Countries
- 1
- Sponsor
- Hospital Geral Roberto Santos
- Drugs
- rivaroxaban
- Conditions
- thromboembolism
01
Overview
Phase 3, randomised, open-label trial of rivaroxaban in thromboembolism, sponsored by Hospital Geral Roberto Santos. Primary endpoint: Thromboembolic events: Stroke, TIA, SBI and SE at 90 days. Started Jul 2018; status: terminated.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Patients with mechanical prosthetic valve replacement at least 3 months post-op, excluding those with severe renal impairment, active liver disease, or high bleeding risk.
04
Endpoints
Primary
Thromboembolic events: Stroke, TIA, SBI and SE
Beyond the preview
Go deeper on NCT03566303.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03566303.